Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats

Toxicology Mechanisms and Methods

Volumn 22, Issue 6, 2012, Pages 488-498

  Kim, Yong Hyun ^a   Park, Seong Mi ^b   Kim, Mina ^b   Kim, Seong Hwan ^a   Lim, Sang Yeob ^a   Ahn, Jeong Cheon ^a   Song, Woo Hyuk ^a   Shim, Wan Joo ^a,b  

^a Korea University   (South Korea)

^b College of Medicine   (South Korea)

Author keywords

Anthracycline cardiomyopathy; antioxidant; malondialdehyde; malondialdehyde to oxidative stress; myocardial fibrosis; statin

Indexed keywords

CARVEDILOL; DOXORUBICIN; MALONALDEHYDE; ROSUVASTATIN; TROPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG EFFECT; DRUG MEGADOSE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART PROTECTION; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SYSTOLIC DYSFUNCTION; TREATMENT DURATION;

EID: 84862249122     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.678406     Document Type: Article

References (39)

1. Abd Elbaky NA, Ali AA, Ahmed RA. 2010. Cardioprotective effect of simvastatin on doxorubicin-induced oxidative cardiotoxicity in rats. J Basic Appl Sci 6:29-38.
2. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, Meric M, Agac MT. 2011. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 58:988-989.
3. Anders RJ, Shanes JG, Zeller FP. 1986. Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low-dose administration. Am Heart J 111:755-759. (Pubitemid 16104592)
4. Arozal W, Sari FR, Watanabe K, Arumugam S, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, Lakshmanan AP, Kobayashi Y, Mito S, Soetikno V, Suzuki K. 2011. carvedilol-afforded protection against daunorubicin-induced cardiomyopathic rats in vivo: Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacol 2011:430-549.
5. Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, Suzuki K, Kodama M, Aizawa Y. 2010. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 274:18-26.
6. Bardeleben RV, Dunkern T, Kaina B, Fritz G. 2002. The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int J Mol Med 10:473-479.
7. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, Madeddu C, Massa E, Mercuro G. 2010. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160:487.e1-487.e7.
8. Chatterjee K, Zhang J, Honbo N, Karliner JS. 2010. Doxorubicin cardiomyopathy. Cardiology 115:155-162.
9. Damrot J, Nübel T, Epe B, Roos WP, Kaina B, Fritz G. 2006. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br J Pharmacol 149:988-997. (Pubitemid 44950802)
10. Davignon J. 2004. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109:III39-III43. (Pubitemid 38786442)
11. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anversa P. 2010. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121:276-292.
12. de Nigris F, Rienzo M, Schiano C, Fiorito C, Casamassimi A, Napoli C. 2008. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer 44:334-340.
13. Iliskovic N, Singal PK. 1997. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 150:727-734. (Pubitemid 27073799)
14. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, Ergin A. 2006. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258-2262. (Pubitemid 44855419)
15. Kawai K, Qin F, Shite J, Mao W, Fukuoka S, Liang CS. 2004. Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 287:H1003-H1012. (Pubitemid 39096644)
16. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM. 2003. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 108:1368-1374. (Pubitemid 37174416)
17. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB. 2004. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279:8290-8299. (Pubitemid 38294721)
18. Martin JH, Krum H. 2007. Statins and clinical outcomes in heart failure. Clin Sci 113:119-127. (Pubitemid 47237908)
19. Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. 1999. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 65: 1265-1274. (Pubitemid 29425963)
20. Mochizuki M, Yano M, Oda T, Tateishi H, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M. 2007. Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49:1722-1732. (Pubitemid 46589924)
21. Noguchi N, Nishino K, Niki E. 2000. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem Pharmacol 59:1069-1076. (Pubitemid 30110499)
22. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallace KB. 2004. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200:159-168. (Pubitemid 39346022)
23. Otto A, Fontaine D, Fontaine J, Berkenboom G. 2005. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol 46:177-184. (Pubitemid 41060210)
24. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. 2008. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51:415-426.
25. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, Kroemer HK, Schultheiss HP, Tschöpe C. 2009. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 69:695-699.
26. Robinson JG. 2008. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol 101:1009-1015.
27. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. 2002. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 185:218-227. (Pubitemid 36062795)
28. Sharma H, Pathan RA, Kumar V, Javed S, Bhandari U. 2011. Antiapoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int J Cardiol 150:193-200.
29. Sicard P, Delemasure S, Korandji C, Segueira-Le Grand A, Lauzier B, Guilland JC, Duvillard L, Zeller M, Cottin Y, Vergely C, Rochette L. 2008. Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res 42:226-236. (Pubitemid 351419909)
30. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C. 2004. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846. (Pubitemid 39222076)
31. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. 1991. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677.
32. Strandberg TE. 2010. Lipid-lowering drugs and heart failure: where do we go after the statin trials? Curr Opin Cardiol 25:385-393.
33. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. 2003. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42:1091-1097. (Pubitemid 37108599)
34. Takemura G, Fujiwara H. 2007. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330-352. (Pubitemid 46295436)
35. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. 2011. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 15(6):CD003917.
36. Yoshida M, Shiojima I, Ikeda H, Komuro I. 2009. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53- apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47:698-705.
37. Yue TL, McKenna PJ, Ruffolo RR Jr, Feuerstein G. 1992. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 214:277-280.
38. Zhai Y, Gao X, Wu Q, Peng L, Lin J, Zuo Z. 2008. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol 587:196-203.
39. Zhou R, Xu Q, Zheng P, Yan L, Zheng J, Dai G. 2008. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol 586:244-250.